The EPO published patent application EP3589653A1 for immune checkpoint therapy compositions with inventors and applicants Kleef, Ralf. The application is classified under C07K 16/28 (antibodies), A61K 41/00 (therapeutic proteins), and C07K 14/55 (cytokines). The patent is designated for all 35 EPC contracting states including all current EU member states, with designations listed for AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.\n\nFor competitors in immune checkpoint therapy development, this A1 publication provides formal notice to assess potential freedom-to-operate implications. The publication initiates a 9-month opposition period during which third parties may file observations. No immediate compliance action is required from non-applicants, but companies developing similar therapeutic approaches should review the claims for overlap with their programs. Applicants seeking national phase entry must monitor the 30-month deadline from the original filing date.